The collaboration between ViaNautis Bio (ViaNautis) and Eli Lilly and Company (Lilly) marks a significant advancement in the field of genetic medicine. This partnership aims to leverage ViaNautis' cutting-edge polyNaut technology to develop precision genetic medicines that can deliver genetic
MilliporeSigma, a prominent player in the life sciences sector, has launched a transformative $76 million investment dedicated to expanding its ADC (antibody-drug conjugates) manufacturing capabilities at its St. Louis, Missouri facility. This monumental investment encapsulates the extensive
Artificial Intelligence (AI) has emerged as a transformative force in numerous sectors, and nowhere is its impact more pronounced than in the field of drug discovery. This field, traditionally marked by high costs, time-consuming processes, and a significant amount of trial and error, is witnessing
Switzerland has established itself as a global leader in the biotech industry, making significant advancements in areas such as cancer treatment, immunotherapy, gene and cell therapy, and more. With a strong focus on personalized and precision medicine, the Swiss biotech sector thrives on
Thermo Fisher Scientific has made a groundbreaking leap in precision medicine with the introduction of the Orbitrap Astral mass spectrometer. This cutting-edge technology ushers in a new era of proteomics and clinical research, fundamentally transforming our approach to precision medicine. Bridging
In an ambitious endeavor to revolutionize cancer treatment, Boehringer Ingelheim and Circle Pharma have entered into a research partnership and license agreement aimed at developing a first-in-class cyclin inhibitor. This groundbreaking collaboration is set to provide novel treatment options for
